Senator Ralph Alvarado Celebrates Expansion of Catalent Pharma Solutions in Winchester, Announcement of Additional Investment
Company will create 300 additional jobs, invest $62 million
WINCHESTER, Ky. (April 15, 2015) – Catalent Pharma Solutions LLC continues to grow in eastern Kentucky. Senator Ralph Alvarado (R-Winchester) joined company officials, Lt. Gov. Crit Luallen and local leaders to cut the ribbon on Catalent’s $52-million expansion. It was also announced today that the company plans to invest an additional $62 million and add 300 more jobs to the Winchester operation.
During the recently completed project, Catalent created 140 full-time jobs and invested $52 million to add 80,000 square feet to its 100,000-square-foot facility on Enterprise Drive. The new $62-million investment, announced today, will be used to create additional square footage and renovate existing space for new equipment. Catalent plans to hire up to 300 workers, including military veterans, over the next five years.
“The Winchester facility has grown through continued investment in technical expertise and capability, an achievement made possible through our associates at Winchester,” said Barry Littlejohns, Catalent’s president of Advanced Delivery Technologies. “Our success spans many significant product launches, some of which are potentially life-saving drugs. We have a flexible business model that supports tailored solutions for our customers and that is of enduring appeal, driving increased demand for our Winchester manufacturing services and attracting both new and existing partners to manufacture.”
Catalent is the leading global provider of advanced drug delivery technologies and development solutions for drugs, biologics and consumer health products. The company employs approximately 8,500 people, including more than 1,000 scientists at 30 facilities on five continents.
Opened in 1992, the Winchester plant currently employs more than 500 people and produces a variety of over-the-counter and prescription drugs in tablets, capsules and powders. The facility has launched more than 100 products for Catalent’s pharmaceutical and consumer health customers.
“I could not be more excited to see such a significant investment made by Catalent Pharma Solutions in my hometown of Winchester,” Alvarado said. “As a physician, it is encouraging to see this pharmaceutical company’s impact on our local economy and in Kentucky’s health care industry as a whole. The new jobs created from this investment certainly will improve the quality of life in our community and provide a landmark for future business investments in the Commonwealth.”
To encourage the new investment and job growth in Winchester, the Kentucky Economic Development Finance Authority (KEDFA) preliminarily approved the company for tax incentives up to $4.5 million through the Kentucky Business Investment program. The performance-based incentive allows a company to keep a portion of its investment over the term of the agreement through corporate income tax credits and wage assessments by meeting job and investment targets.
KEDFA also approved Catalent for tax benefits up to $700,000 through the Kentucky Enterprise Initiative Act, which allows approved companies to recoup Kentucky sales and use tax on construction costs, building fixtures, equipment used in research and development and electronic processing equipment.
For more information on Catalent Pharma Solutions, visit www.catalent.com.
A detailed community profile for Winchester (Clark County) can be viewed here.